Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Cartesian Therapeutics (RNAC) Long-Term Debt Repayments (2017 - 2023)

Historic Long-Term Debt Repayments for Cartesian Therapeutics (RNAC) over the last 5 years, with Q3 2023 value amounting to $24.9 million.

  • Cartesian Therapeutics' Long-Term Debt Repayments changed N/A to $24.9 million in Q3 2023 from the same period last year, while for Dec 2024 it was $24.9 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $27.5 million for FY2023, which is N/A changed from last year.
  • Per Cartesian Therapeutics' latest filing, its Long-Term Debt Repayments stood at $24.9 million for Q3 2023.
  • Cartesian Therapeutics' Long-Term Debt Repayments' 5-year high stood at $24.9 million during Q3 2023, with a 5-year trough of $700000.0 in Q3 2019.
  • Moreover, its 3-year median value for Long-Term Debt Repayments was $2.1 million (2019), whereas its average is $7.8 million.
  • The largest annual percentage gain for Cartesian Therapeutics' Long-Term Debt Repayments in the last 5 years was 205900.0% (2020), contrasted with its biggest fall of 205900.0% (2020).
  • Over the past 3 years, Cartesian Therapeutics' Long-Term Debt Repayments (Quarter) stood at $2.1 million in 2019, then soared by 619.67% to $15.1 million in 2020, then surged by 64.57% to $24.9 million in 2023.
  • Its Long-Term Debt Repayments stands at $24.9 million for Q3 2023, versus $15.1 million for Q3 2020 and $2.1 million for Q2 2020.